Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370772![]() (US10239835, Example 00324) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.41 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370754![]() (US10239835, Example 00306) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.44 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370814![]() (US10239835, Example 00365) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.24 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370813![]() (US10239835, Example 00364) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.25 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370756![]() (US10239835, Example 00308) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.72 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370745![]() (US10239835, Example 00297) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.96 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370743![]() (US10239835, Example 00295) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.20 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370781![]() (US10239835, Example 00333) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.81 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370815![]() (US10239835, Example 00366) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.30 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370816![]() (US10239835, Example 00367) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370769![]() (US10239835, Example 00321) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.62 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370797![]() (US10239835, Example 00349) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.78 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370802![]() (US10239835, Example 00354) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.36 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370768![]() (US10239835, Example 00320) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.60 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370744![]() (US10239835, Example 00296) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 10.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370676![]() (US10239835, Example 00228) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370678![]() (US10239835, Example 00230) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370782![]() (US10239835, Example 00334) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 14.4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370755![]() (US10239835, Example 00307) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 16.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370681![]() (US10239835, Example 00233) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 17.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370727![]() (US10239835, Example 00279) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 17.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370694![]() (US10239835, Example 00246) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 18 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370809![]() (US10239835, Example 00361) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 19.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370817![]() (US10239835, Example 00368) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 20 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370812![]() (US10239835, Example 00363) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 20.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370749![]() (US10239835, Example 00301) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 20.9 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370757![]() (US10239835, Example 00309) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 21.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370784![]() (US10239835, Example 00336) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 23.4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370794![]() (US10239835, Example 00346) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 26.3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370801![]() (US10239835, Example 00353) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 26.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370767![]() (US10239835, Example 00319) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 29.3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370714![]() (US10239835, Example 00266) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 30.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370722![]() (US10239835, Example 00274) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 30.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370740![]() (US10239835, Example 00292) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 37.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370800![]() (US10239835, Example 00352) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 38 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370765![]() (US10239835, Example 00317) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 41.1 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370711![]() (US10239835, Example 00263) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 41.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370698![]() (US10239835, Example 00250) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 46.4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370675![]() (US10239835, Example 00227) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 47 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370702![]() (US10239835, Example 00254) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 47.4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370787![]() (US10239835, Example 00339) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 50.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370712![]() (US10239835, Example 00264) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 51.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370705![]() (US10239835, Example 00257) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 52.1 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370721![]() (US10239835, Example 00273) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 53.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370689![]() (US10239835, Example 00241) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 53.4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370758![]() (US10239835, Example 00310) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 55.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370718![]() (US10239835, Example 00270) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 57.3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370683![]() (US10239835, Example 00235) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 58.3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370799![]() (US10239835, Example 00351) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 60.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370677![]() (US10239835, Example 00229) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 61.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370710![]() (US10239835, Example 00262) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 65.8 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370701![]() (US10239835, Example 00253) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 68.2 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370742![]() (US10239835, Example 00294) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 68.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370713![]() (US10239835, Example 00265) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 70.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370789![]() (US10239835, Example 00341) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 72.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370808![]() (US10239835, Example 00360) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 74 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370760![]() (US10239835, Example 00312) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 74.1 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370790![]() (US10239835, Example 00342) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 77.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370750![]() (US10239835, Example 00302) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 80.7 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370684![]() (US10239835, Example 00236) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 81.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370720![]() (US10239835, Example 00272) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 83.9 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370692![]() (US10239835, Example 00244) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 84.5 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370724![]() (US10239835, Example 00276) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 90 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370690![]() (US10239835, Example 00242) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 94.6 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370699![]() (US10239835, Example 00251) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 102 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370725![]() (US10239835, Example 00277) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 112 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370762![]() (US10239835, Example 00314) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 112 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370811![]() (US10239835, Example 00362) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 113 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370788![]() (US10239835, Example 00340) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 117 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370730![]() (US10239835, Example 00282) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 134 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370770![]() (US10239835, Example 00322) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 139 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370707![]() (US10239835, Example 00259) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 140 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370771![]() (US10239835, Example 00323) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 149 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370776![]() (US10239835, Example 00328) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 163 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370786![]() (US10239835, Example 00338) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 177 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370731![]() (US10239835, Example 00283) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 188 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370738![]() (US10239835, Example 00290) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 191 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370798![]() (US10239835, Example 00350) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 210 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370761![]() (US10239835, Example 00313) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 219 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370766![]() (US10239835, Example 00318) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 225 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370807![]() (US10239835, Example 00359) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 230 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370785![]() (US10239835, Example 00337) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 243 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370793![]() (US10239835, Example 00345) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 249 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370719![]() (US10239835, Example 00271) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 250 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370685![]() (US10239835, Example 00237) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 253 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370703![]() (US10239835, Example 00255) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 267 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370780![]() (US10239835, Example 00332) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 308 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370695![]() (US10239835, Example 00247) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 367 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370737![]() (US10239835, Example 00289) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 409 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370696![]() (US10239835, Example 00248) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 434 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370773![]() (US10239835, Example 00325) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 435 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370739![]() (US10239835, Example 00291) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 440 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370792![]() (US10239835, Example 00344) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 466 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370686![]() (US10239835, Example 00238) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 493 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370777![]() (US10239835, Example 00329) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 547 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370779![]() (US10239835, Example 00331) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 569 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370778![]() (US10239835, Example 00330) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370680![]() (US10239835, Example 00232) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 699 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370796![]() (US10239835, Example 00348) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.04E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370764![]() (US10239835, Example 00316) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.08E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370763![]() (US10239835, Example 00315) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.15E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370679![]() (US10239835, Example 00231) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.26E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370709![]() (US10239835, Example 00261) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.33E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370795![]() (US10239835, Example 00347) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.66E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370704![]() (US10239835, Example 00256 | US10239835, Example 00...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.98E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370723![]() (US10239835, Example 00275) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.37E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370728![]() (US10239835, Example 00280) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.78E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370717![]() (US10239835, Example 00269) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.92E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370733![]() (US10239835, Example 00285) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.29E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370803![]() (US10239835, Example 00355) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370783![]() (US10239835, Example 00335) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.78E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370804![]() (US10239835, Example 00356) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.37E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370729![]() (US10239835, Example 00281) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.47E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370704![]() (US10239835, Example 00256 | US10239835, Example 00...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.89E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370734![]() (US10239835, Example 00286) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.22E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370752![]() (US10239835, Example 00304) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.24E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370726![]() (US10239835, Example 00278) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370735![]() (US10239835, Example 00287) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370688![]() (US10239835, Example 00240) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370751![]() (US10239835, Example 00303) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370715![]() (US10239835, Example 00267) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370741![]() (US10239835, Example 00293) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370697![]() (US10239835, Example 00249) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370736![]() (US10239835, Example 00288) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370775![]() (US10239835, Example 00327) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370706![]() (US10239835, Example 00258) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370691![]() (US10239835, Example 00243) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370806![]() (US10239835, Example 00358) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370687![]() (US10239835, Example 00239) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370732![]() (US10239835, Example 00284) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370747![]() (US10239835, Example 00299) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370791![]() (US10239835, Example 00343) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370682![]() (US10239835, Example 00234) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370708![]() (US10239835, Example 00260) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370748![]() (US10239835, Example 00300) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370753![]() (US10239835, Example 00305) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370759![]() (US10239835, Example 00311) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370774![]() (US10239835, Example 00326) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370805![]() (US10239835, Example 00357) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370693![]() (US10239835, Example 00245) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370746![]() (US10239835, Example 00298) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
GluN1/GluN2B NMDA receptor (Homo sapiens (Human)) | BDBM370700![]() (US10239835, Example 00252) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
CADENT THERAPEUTICS, INC. US Patent | Assay Description Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st... | US Patent US10239835 (2019) BindingDB Entry DOI: 10.7270/Q2F19207 | |||||||||||
More data for this Ligand-Target Pair |